---
schema_version: "secwatch.filing_event.v1"
accession: "0001793229-23-000119"
form_type: "8-K"
ticker: "CTEV"
cik: "0001793229"
company_name: "Claritev Corp"
filed_at: "2023-11-07T23:59:59+00:00"
generated_at: "2026-06-08T16:52:49.713743+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# MultiPlan Q3 2023 revenue $242.8M, net loss $24.1M; FY guidance tightened

## Summary
- Q3 2023 revenue $242.8M (-3.1% YoY); net loss $24.1M vs net income $19.7M in Q3 2022.
- Adjusted EBITDA $152.3M; Free Cash Flow $49.7M, down from $88.2M prior year.
- Repurchased $46.1M face value of 5.75% Senior Unsecured Notes in open market during Q3.
- FY 2023 guidance updated: revenue $960-970M (from $950-980M), Adjusted EBITDA $615-625M (from $615-635M).
- Identified ~$5.8B in potential medical cost savings in Q3, up 7% YoY.

## SEC filing metadata
- accession: 0001793229-23-000119
- form_type: 8-K
- ticker: CTEV
- cik: 0001793229
- company_name: Claritev Corp
- filed_at: 2023-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1793229/000179322923000119/0001793229-23-000119-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1793229/000179322923000119/mpln-20231107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001793229-23-000119
- JSON: https://secwatch.observer/filing/0001793229-23-000119.json
- Plain text: https://secwatch.observer/filing/0001793229-23-000119.txt

## Key facts
- Earnings Releases
  Claritev Corp reported Full Year 2023 results: revenue $960 million to $970 million. Guidance reaffirmed.
  - Period: Full Year 2023
  - Revenue: $960 million to $970 million
  - Guidance: reaffirmed
  - Result: guidance update
  source text: as detailed in the table below. All other guidance items remain unchanged. Financial Metric Prior FY 2023 Guidance Revised FY 2023 Guidance Revenues $950 million to $980 million $960 million to $970 million Adjusted EBITDA 1 $615 million to $635 million $615 million to $625 million Interest expense $325 million to $335 million Cash flow from operations 2 $160 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1793229/000179322923000119/0001793229-23-000119-index.htm
- Earnings Releases
  Claritev Corp reported the third quarter ended September 30, 2023 results: revenue $242.8 million, net income Net loss of $24.1 million. Guidance reaffirmed.
  - Period: the third quarter ended September 30, 2023
  - Revenue: $242.8 million
  - Net income: Net loss of $24.1 million
  - Guidance: reaffirmed
  - Result: reported results
  source text: Act, regardless of any general incorporation language in such filings. --- EX-99.1 (EX-99.1) --- RELEASE MultiPlan Reports Third Quarter 2023 Results – Q3 2023 Revenues of $242.8 million, Net Loss of $24.1 million, and Adjusted EBITDA of $152.3 million – Identified potential medical cost savings of approximately $5.8 billion in Q3 2023, up 2% from Q2 2023 and up
  evidence_url: https://www.sec.gov/Archives/edgar/data/1793229/000179322923000119/0001793229-23-000119-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.